FDA & CDSCO Compliance in Pharma and Medical Device Videos: What You Must Know
The Regulatory Landscape for Healthcare Video in India
Promotional video content for pharmaceutical products and medical devices operates in a highly regulated environment. In India, the Central Drugs Standard Control Organisation (CDSCO) and the Drugs and Cosmetics Act (1940) govern what can and cannot be claimed in promotional materials.
For companies that export to or operate in the US, FDA's 21 CFR Part 202 (prescription drug advertising) and the Office of Prescription Drug Promotion (OPDP) guidelines apply.
Getting this wrong is expensive. Regulatory letters, mandatory corrective communications, and reputational damage are all real consequences of non-compliant promotional videos.
---
What Makes a Video "Promotional"?
Under CDSCO guidance, any video that:
- Names a specific drug or device
- Implies clinical benefit or superiority
- Features a healthcare professional endorsing the product
- Is distributed to prescribers, patients, or the public
...is considered promotional and must comply with applicable regulations.
---
The 5 Non-Negotiables for Compliant Pharma Videos
1. Approved Indications Only
Never imply use for an indication that is not listed in the approved label. Off-label promotion is illegal in both India and the US.2. Fair Balance
Any discussion of benefits must be accompanied by a fair presentation of risks, side effects, and contraindications — either in the video itself or in accompanying materials.3. Substantiation of Claims
Every efficacy or safety claim must be backed by peer-reviewed clinical data. "Best in class" or "superior efficacy" without clinical substantiation is a common violation.4. No Misleading Visual Representations
Graphics that exaggerate the size, speed, or mechanism of a drug's effect — even if the audio is accurate — can constitute a misleading representation.5. Approval Workflow
Promotional video content should pass through Medical, Legal, and Regulatory (MLR) review before publication. Build this into your production timeline.---
Common Compliance Mistakes in Pharma Videos
| Mistake | Risk | |---------|------| | Testimonial from KOL without disclosure of financial relationship | Violates transparency guidelines | | Animation showing mechanism of action not supported by clinical data | Misleading representation | | CTA directing HCPs to a URL without ISI (Important Safety Information) | Incomplete fair balance | | Patient testimonial without IRB-approved consent and disclosure | Privacy violation + regulatory risk | | Comparison to competitor without head-to-head clinical evidence | Unsubstantiated comparative claim |
---
How to Structure a Compliant MLR-Ready Video Brief
A production brief that will pass MLR review should include:
1. Approved indication (verbatim from label) 2. Approved claims (referenced to clinical study) 3. Required disclosures (ISI, risk language) 4. Audience (HCP vs. patient vs. payer) 5. Distribution channel (congress, sales force, digital) 6. Review timeline (allow 4–6 weeks for MLR in large organisations)
---
BanyanTree's Compliance-First Production Process
We have produced pharma video content for CDSCO-regulated products across Ahmedabad, Mumbai, and Hyderabad for over 30 years. Our process includes:
- Pre-production compliance review of all scripts and claims
- Collaboration with your MLR team during scripting
- Post-production MLR annotation support (timestamps for reviewer ease)
- Full documentation package for regulatory files
[Speak to our pharma video team today.](/contact-us)